Co-Diagnostics, Inc. (CODX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.1800 |
| Open | 1.1600 |
| Bid | 1.1900 x 2200 |
| Ask | 1.3100 x 900 |
| Day's Range | 1.1500 - 1.3391 |
| 52 Week Range | 0.9750 - 3.3300 |
| Volume | |
| Avg. Volume | 74,300 |
| Market Cap | 39.449M |
| Beta (5Y Monthly) | -0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CODX
Related Research
- Co-Diagnostics, Inc.VIR: What does Argus have to say about VIR?VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat4 days agoArgus Research
- PR Newswire
Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023.
- PR Newswire
Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023.
- PR Newswire
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*. The amount awarded is $8.976 million.
